MEVROMETOSTAT (PF-06821497) IN COMBINATION WITH ENZALUTAMIDE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE: THE PHASE 3, RANDOMIZED MEVPRO-1 STUDY

被引：0
|
作者：
Neeraj, Agarwal [1 ]
Michael, T. Schweizer [1 ]
Elena, Castro [1 ]
Arun, A. Azad [1 ]
Daniel, J. George [1 ]
Jayeta, Chakrabarti [1 ]
Sujata, Narayanan [1 ]
Yiyun, Tang [1 ]
Karim, Fizazi [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst NCI CCC, Salt Lake City, UT USA
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2025年 / 43卷 / 03期
关键词：
D O I：
10.1016/j.urolonc.2024.12.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
    Efstathiou, Eleni
    Titus, Mark
    Wen, Sijin
    Troncoso, Patricia
    Hoang, Anh
    Corn, Paul
    Prokhorova, Ina
    Araujo, John
    Dmuchowski, Carl
    Melhem-Bertrandt, Amal
    Patil, Shiva
    Logothetis, Christopher J.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
  • [2] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
    La, Jennifer
    Wang, Lin
    Corrigan, June K.
    Lang, Deborah
    Lee, Michelle H.
    Do, Nhan V.
    Brophy, Mary T.
    Paller, Channing J.
    Fillmore, Nathanael R.
    JAMA NETWORK OPEN, 2024, 7 (08)
  • [3] A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shore, Neal
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph
    Costin, Dan
    Adra, Nabil
    Cullberg, Marie
    Teruel, Carlos Fernandez
    Morris, Thomas
    CLINICAL GENITOURINARY CANCER, 2023, 21 (02) : 278 - 285
  • [4] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Rana, Dikshyanta
    Geue, Claudia
    Baillie, Kelly
    Pan, Jiafeng
    Mueller, Tanja
    Laskey, Jennifer
    Bennie, Marion
    Clarke, Julie
    Jones, Robert J.
    Brown, Ailsa
    Wu, Olivia
    PHARMACOECONOMICS-OPEN, 2022, 6 (02) : 303 - 313
  • [5] Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
    Dikshyanta Rana
    Claudia Geue
    Kelly Baillie
    Jiafeng Pan
    Tanja Mueller
    Jennifer Laskey
    Marion Bennie
    Julie Clarke
    Robert J. Jones
    Ailsa Brown
    Olivia Wu
    PharmacoEconomics - Open, 2022, 6 : 303 - 313
  • [6] Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Buonerba, Carlo
    Sonpavde, Guru
    Pond, Gregory Russell
    Pagliuca, Martina
    Rossetti, Sabrina
    Facchini, Gaetano
    Scagliarini, Sarah
    Daniele, Bruno
    Federico, Piera
    Morelli, Franco
    Carteni, Giacomo
    Ferro, Matteo
    Lucarelli, Giuseppe
    Bellelli, Teresa
    De Placido, Sabino
    di Lorenzo, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] A phase I study of capivasertib in combination with abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
    Shore, Neal D.
    Mellado, Begona
    Shah, Satish
    Hauke, Ralph J.
    Costin, Dan
    Morris, Thomas
    Anjum, Rana
    Szijgyarto, Zsolt
    Verheijen, Remy B.
    Cullberg, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [8] Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide
    Modena, Alessandra
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Tortora, Giampaolo
    Massari, Francesco
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (09) : 1037 - 1048
  • [9] Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer
    Zhang, Tian
    Zhu, Jason
    George, Daniel J.
    Armstrong, Andrew J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 473 - 485
  • [10] Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
    Schweizer, Michael Thomas
    Penkov, Konstantin
    Choudhury, Atish Dipankar
    Calvo, Emiliano
    Frank, Richard C.
    Liu, Li
    Mittapalli, Rajendar K.
    Tougias, Jessica
    Andreu-Vieyra, Claudia
    Bowler, Timothy Geoffrey
    Soman, Neelesh
    Garmezy, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345